1 |
Brannon-Peppas L, Blanchette JO (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev, 56, 1649-59.
DOI
ScienceOn
|
2 |
Danhier F, Lecouturier N, Vroman B, et al (2009). Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J Controlled Release, 133, 11-7.
DOI
ScienceOn
|
3 |
Demeure MJ, Stephan E, Gonzales P, et al (2008). Pre-clinical evidence for nab-paclitaxel efficacy in the treatment of adrenocortical cancer. J Clin Oncol, 26, 22070.
|
4 |
Desai N, Trieu V, Yao Z, et al (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12, 1317-24.
DOI
ScienceOn
|
5 |
Fader AN, Rose PG (2009). Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer, 19, 1281-3.
DOI
ScienceOn
|
6 |
Gradishar WJ, Tjulandin S, Davidson N, et al (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23, 7794-803.
DOI
ScienceOn
|
7 |
Green MR, Manikhas GM, Orlov S, et al (2006). Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol, 17, 1263-8.
DOI
ScienceOn
|
8 |
HTTP://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm 16.05.2013.
|
9 |
HTTP://www.has-sante.frportailuploaddocsapplicationpdf2011-01abraxane_ct_7088.pdf 10.02.2013.
|
10 |
Kratz F (2008). Albumin as drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Controlled Release, 132, 171-83.
DOI
ScienceOn
|
11 |
Lin LY, Karwa A, Kostelc JG, et al (2012). Paclitaxel-loaded SCK nanoparticles: an investigation of loading capacity and cell killing abilities. In Vitro Mol Pharmaceutics, 9, 2248-55.
DOI
ScienceOn
|
12 |
Saunders DE, Dwayne-Lawrence W, Christensen C, et al (1997). Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int J Cancer, 70, 214-20.
DOI
|
13 |
Sparreboom A, Scripture CD, Treiu V, et al (2005). Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound Paclitaxel (ABI-007) and Paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res, 11, 4136-43.
DOI
ScienceOn
|
14 |
Topcul M, Cetin I (2013). Nanotechnology in the field of clinical oncology. Marmara Med J, 26, 1-4.
|
15 |
Wiedenmann N, Valdecanas D, Hunter N, et al (2007). One hundred thirty-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res, 13, 1868-74.
DOI
ScienceOn
|
16 |
Yang Y, Niu X, Zhang Q, et al (2010). In vitro inhibiting effect of albumin-bound paclitaxel on human osteosarcoma cell os-732. Shandong Med J, 50, 24-26.
|
17 |
Yang Y, Niu X, Zhang Q, et al (2012). The efficacy of Abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine. Am J Med Sci, 344, 199-205.
DOI
ScienceOn
|
18 |
Zhang C, Awasthi N, Schwartz MA, et al (2013). Superior antitumor activity of nanoparticle albumin- bound Paclitaxel in experimental gastric cancer. Plos One, 8, 1-10.
|